The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load
Abstract The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with re...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-05541-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335130950205440 |
|---|---|
| author | Petr Waldauf Ivana Jurisinova Eva Svobodova Michaela Diblickova Tomas Tencer Jan Zavora Gabriela Smela Lenka Kupidlovska Vaclava Adamkova Marta Fridrichova Karolina Jerabkova Jakub Mikes Frantisek Duska Ladislav Dusek Martin Balik |
| author_facet | Petr Waldauf Ivana Jurisinova Eva Svobodova Michaela Diblickova Tomas Tencer Jan Zavora Gabriela Smela Lenka Kupidlovska Vaclava Adamkova Marta Fridrichova Karolina Jerabkova Jakub Mikes Frantisek Duska Ladislav Dusek Martin Balik |
| author_sort | Petr Waldauf |
| collection | DOAJ |
| description | Abstract The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with remdesivir were compared with the controls. Baseline plasmatic creatinine (PCr) < 150 µmol/l in patients on remdesivir decreased equally to controls (− 6 (− 20; 9) vs. − 8 (− 24; 2) µmol/l, n = 170, p = 0.11). The similar trends were found for baseline PCr ≥ 150 µmol/l (− 57 (− 129; − 15) µmol/l for remdesivir group vs. − 65 (− 111; − 7) µmol/l, p > 0.9). Changes of PCr were independent of the remdesivir therapy, the statistically significant confounders were baseline PCr levels (p < 0.001), hospital length-of-stay (p < 0.001), leukocyte-to-lymphocyte ratio (p = 0.025). The plasmatic urea (PU) mildly increased in the remdesivir group (1 (− 2; 5) mmol/l vs. 0 (− 3; 2) mmol/l in the controls, p = 0.009), its levels were related to remdesivir (p = 0.026), age (p = 0.002), PCr (p < 0.001), hospital length-of-stay (p < 0.001), IPPV (p = 0.035). Regarding the liver function tests the significant relationships to remdesivir therapy were found only for GGT (p = 0.007) and ALT (p = 0.044). The levels of PCr were decreasing over the hospitalisation period including patients with mild-to-moderate renal insufficiency. The multivariate regression analysis excluded an impact of remdesivir on the PCr changes yet admitted an impact on the levels of urea, GGT and ALT. |
| format | Article |
| id | doaj-art-24e2e4e690894f56aab3d01e6b83df49 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-24e2e4e690894f56aab3d01e6b83df492025-08-20T03:45:23ZengNature PortfolioScientific Reports2045-23222025-07-011511810.1038/s41598-025-05541-9The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral loadPetr Waldauf0Ivana Jurisinova1Eva Svobodova2Michaela Diblickova3Tomas Tencer4Jan Zavora5Gabriela Smela6Lenka Kupidlovska7Vaclava Adamkova8Marta Fridrichova9Karolina Jerabkova10Jakub Mikes11Frantisek Duska12Ladislav Dusek13Martin Balik14Department of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalDepartment of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University HospitalDepartment of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University HospitalDepartment of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University HospitalDepartment of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalInstitute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University HospitalInstitute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University HospitalInstitute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University HospitalInstitute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University and General University HospitalDepartment of Laboratory Diagnostics, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalDepartment of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalDepartment of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalDepartment of Anaesthesiology and Intensive Care, 3rd Faculty of Medicine, Charles University and Kralovske Vinohrady University HospitalInstitute of Health Information and Statistics of the Czech Republic, Faculty of Medicine, Masaryk UniversityDepartment of Anaesthesiology and Intensive Care, 1st Faculty of Medicine, Charles University and General University HospitalAbstract The impact of remdesivir on renal and liver functions remains a matter of concern in advanced COVID-19 patients with high illness severity and presence of viral load. The laboratory results of the 114 patients (males 55.8%, age 71 (59; 77) years) with a detectable viral load treated with remdesivir were compared with the controls. Baseline plasmatic creatinine (PCr) < 150 µmol/l in patients on remdesivir decreased equally to controls (− 6 (− 20; 9) vs. − 8 (− 24; 2) µmol/l, n = 170, p = 0.11). The similar trends were found for baseline PCr ≥ 150 µmol/l (− 57 (− 129; − 15) µmol/l for remdesivir group vs. − 65 (− 111; − 7) µmol/l, p > 0.9). Changes of PCr were independent of the remdesivir therapy, the statistically significant confounders were baseline PCr levels (p < 0.001), hospital length-of-stay (p < 0.001), leukocyte-to-lymphocyte ratio (p = 0.025). The plasmatic urea (PU) mildly increased in the remdesivir group (1 (− 2; 5) mmol/l vs. 0 (− 3; 2) mmol/l in the controls, p = 0.009), its levels were related to remdesivir (p = 0.026), age (p = 0.002), PCr (p < 0.001), hospital length-of-stay (p < 0.001), IPPV (p = 0.035). Regarding the liver function tests the significant relationships to remdesivir therapy were found only for GGT (p = 0.007) and ALT (p = 0.044). The levels of PCr were decreasing over the hospitalisation period including patients with mild-to-moderate renal insufficiency. The multivariate regression analysis excluded an impact of remdesivir on the PCr changes yet admitted an impact on the levels of urea, GGT and ALT.https://doi.org/10.1038/s41598-025-05541-9RemdesivirSARS-CoV-2Viral loadRenal functionLiver function testsIntensive care |
| spellingShingle | Petr Waldauf Ivana Jurisinova Eva Svobodova Michaela Diblickova Tomas Tencer Jan Zavora Gabriela Smela Lenka Kupidlovska Vaclava Adamkova Marta Fridrichova Karolina Jerabkova Jakub Mikes Frantisek Duska Ladislav Dusek Martin Balik The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load Scientific Reports Remdesivir SARS-CoV-2 Viral load Renal function Liver function tests Intensive care |
| title | The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load |
| title_full | The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load |
| title_fullStr | The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load |
| title_full_unstemmed | The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load |
| title_short | The impact of remdesivir on renal and liver functions in severe COVID-19 patients with presence of viral load |
| title_sort | impact of remdesivir on renal and liver functions in severe covid 19 patients with presence of viral load |
| topic | Remdesivir SARS-CoV-2 Viral load Renal function Liver function tests Intensive care |
| url | https://doi.org/10.1038/s41598-025-05541-9 |
| work_keys_str_mv | AT petrwaldauf theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT ivanajurisinova theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT evasvobodova theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT michaeladiblickova theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT tomastencer theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT janzavora theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT gabrielasmela theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT lenkakupidlovska theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT vaclavaadamkova theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT martafridrichova theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT karolinajerabkova theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT jakubmikes theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT frantisekduska theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT ladislavdusek theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT martinbalik theimpactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT petrwaldauf impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT ivanajurisinova impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT evasvobodova impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT michaeladiblickova impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT tomastencer impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT janzavora impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT gabrielasmela impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT lenkakupidlovska impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT vaclavaadamkova impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT martafridrichova impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT karolinajerabkova impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT jakubmikes impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT frantisekduska impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT ladislavdusek impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload AT martinbalik impactofremdesivironrenalandliverfunctionsinseverecovid19patientswithpresenceofviralload |